Robert A. Gardiner

Clinical liquid biopsy (e.g., blood or urine) specimens, as a minimally invasive source of crucial molecular information, continue to grow in importance for efficacious targeted cancer treatment. Yet, current molecular profiling technologies are still confined to centralized laboratory testing, which escalates testing costs, result turnaround time, and patient anxiety. Crucially, there is also a scarcity of purposeful clinical validation studies to rigorously evaluate emerging liquid biopsy technologies from research settings to facilitate clinical translation. Here, we report liquid biopsy biosensor advancements in achieving rapid, accurate, and decentralized molecular profiling of a clinically accredited prostate cancer (PCa) urinary circulating RNA biomarker panel. This biosensor approach, termed ‘Accelerated non‐inVasive bioAnalyte testing And Reporting’ (AVATAR), integrates accelerated isothermal assay chemistry and wireless mobile operation capabilities onto a portable electrochemical readout platform. AVATAR enables easy operational control and result display with a custom mobile app following liquid biopsy specimen collection. Using independent training ( n = 124) and validation ( n = 114) PCa clinical urinary specimen cohorts, we showed AVATAR achieved superior PCa risk stratification to current clinical PCa testing with area‐under‐curve values of 0.88 (95% confidence interval: 0.84−0.92) and 0.86 (95% confidence interval: 0.83−0.89), respectively within 55 min of assay time. To further accelerate AVATAR for using PCa liquid biopsies as a surrogate for invasive tissue sampling, we designed a tailored multi‐year PCa follow‐up study with individual patient liquid biopsy specimens showing strong molecular biomarker correlation with comprehensive transcriptomic sequencing of matched tissue specimens ( n = 39). By creating this bespoke biosensor technology clinical translation framework, we demonstrated AVATAR for decentralized PCa liquid biopsy molecular profiling to augment clinical precision cancer management planning.

A randomised control trial of salvage radiotherapy and androgen deprivation therapy following prostatectomy: commentary on five year follow-up findings

Prospecting for prostate cancer with precision medicine